- Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
- Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
- Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
- Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
- Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
- Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
- Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
- Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
- Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
More ▼
Key statistics
On Wednesday, Alterity Therapeutics Ltd (ATHE:NAQ) closed at 2.33, 50.32% above the 52 week low of 1.55 set on Feb 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.14 |
---|---|
High | 2.50 |
Low | 2.14 |
Bid | 2.16 |
Offer | 2.40 |
Previous close | 2.13 |
Average volume | 277.84k |
---|---|
Shares outstanding | 8.73m |
Free float | 4.20m |
P/E (TTM) | -- |
Market cap | 20.27m USD |
EPS (TTM) | -1.93 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 20:59 BST.
More ▼